Almost everyone will eventually develop drug resistance.
In the long struggle against one of cancer's most adaptive adversaries, researchers at Oregon Health & Science University have found that a drug already trusted in breast cancer treatment may help close the escape routes that leukemia cells use to survive. By pairing palbociclib with venetoclax, scientists observed something rare in oncology: a combination that doesn't merely improve outcomes, but appears to dismantle multiple survival strategies at once. For the more than 20,000 Americans diagnosed each year with acute myeloid leukemia — a disease that has resisted every attempt to push its five-year survival rate meaningfully higher — this discovery represents a carefully reasoned hope, not yet proven in patients, but grounded in the shared biology that connects cancers we once thought had little in common.
- Nearly every AML patient eventually develops resistance to venetoclax, the current standard therapy, leaving oncologists with few reliable options when the disease adapts.
- Tested against 24 competing drug combinations across more than 300 patient samples, the venetoclax-palbociclib pairing emerged as the clear frontrunner — a result that held in both human tissue and mouse models.
- The combination works by blocking the protein-production surge that AML cells use to survive venetoclax, while a CRISPR screen revealed it simultaneously disables multiple survival pathways — making resistance far harder to achieve.
- In mice carrying venetoclax-resistant human leukemia cells, the drug alone offered no survival benefit; the combination kept most animals alive for nearly a year, with one still living when the study concluded.
- The research team, including lead author and breast cancer survivor Melissa Stewart, is already evaluating related drugs and positioning the combination for clinical trials — the critical test of whether laboratory promise translates to human lives.
Researchers at Oregon Health & Science University have identified a drug combination that may help acute myeloid leukemia patients overcome one of oncology's most persistent obstacles: the near-inevitable resistance that develops to their own treatment.
The discovery came from a methodical search through more than 300 AML patient samples, in which scientists tested 25 drug combinations to find ways of extending the effectiveness of venetoclax, the FDA-approved standard therapy. Adding palbociclib — already approved for breast cancer — produced results that were significantly stronger and more durable than venetoclax alone, a finding confirmed in both human tissue and mice carrying human leukemia cells.
The stakes are considerable. More than 20,000 Americans are diagnosed with AML annually, and while venetoclax transformed initial treatment responses after its approval in 2019, almost all patients eventually develop resistance. The five-year survival rate has remained stubbornly fixed between 25 and 40 percent. When AML cells encounter venetoclax, they adapt by accelerating protein production — an escape mechanism that palbociclib appears to block by regulating the cellular machinery responsible for manufacturing proteins. A genome-wide CRISPR screen further revealed that the two drugs together disable multiple survival pathways simultaneously, a redundancy that may make resistance far more difficult to achieve.
The difference in mouse models was striking. Venetoclax alone offered no survival benefit in animals carrying resistance-causing mutations. With the combination, most mice lived 11 to 12 months — and one remained alive at the study's end.
Lead author Melissa Stewart, a breast cancer survivor who now conducts research at the same institution where she was treated, brought personal weight to the work. Corresponding author Jeffrey Tyner noted that the finding reflects a broader truth in cancer biology: that the molecular machinery driving different cancers can overlap in ways that make treatments transferable across disease types. The team is already evaluating related breast cancer drugs and moving toward clinical trials — the necessary next step in determining whether this laboratory breakthrough can finally shift a survival curve that has resisted change for years.
Researchers at Oregon Health & Science University have identified a drug pairing that may help acute myeloid leukemia patients escape one of the most stubborn problems in cancer treatment: the development of resistance to their own medicine.
The discovery emerged from a systematic hunt through more than 300 patient samples. The team tested 25 different drug combinations, looking for ways to make venetoclax—a standard AML therapy approved by the FDA in 2019—work better and last longer. What they found was that adding palbociclib, a drug already approved for breast cancer, produced significantly stronger and more durable results than venetoclax alone. The finding held up in human tissue samples and in mice carrying human leukemia cells.
The problem they're trying to solve is nearly universal. More than 20,000 Americans are diagnosed with AML each year, making it one of the most common and aggressive forms of leukemia. Since venetoclax combined with azacitidine became standard treatment six years ago, it has improved how patients respond initially and how they feel. But almost everyone eventually develops resistance. The five-year survival rate remains stuck between 25 and 40 percent—a ceiling that hasn't budged despite the drug's arrival.
When AML cells encounter venetoclax alone, they adapt by ramping up their protein production, a shift that allows them to survive the drug's assault. Palbociclib blocks this escape route by regulating the cellular machinery that manufactures proteins. In patient samples that responded strongly to the combination, researchers observed a clear shutdown of genes involved in protein synthesis. A genome-wide CRISPR screen revealed something else important: the two drugs work together to disable multiple survival pathways, not just one. This redundancy matters because it suggests the combination might overcome resistance mechanisms that would otherwise defeat a single drug.
In mouse models implanted with human AML cells carrying mutations known to cause venetoclax resistance, the difference was stark. Venetoclax alone extended survival not at all. With the combination, most mice lived 11 to 12 months, and one was still alive when the study ended. The work was published in Cell Reports Medicine and grew directly out of the Beat AML 1.0 program, a national initiative designed to expand treatment options for this disease.
Melissa Stewart, the study's lead author and a research assistant professor at OHSU, brings a personal dimension to the work. She is a breast cancer survivor treated at the same institution where she now conducts research. That experience shaped her motivation: the hope that research and clinical trials can bring to patients. Jeffrey Tyner, the study's corresponding author and a co-leader of Beat AML, emphasized that the finding illustrates a broader principle in cancer biology. "Some might ask why a breast cancer drug would work in AML," he said. "But biology can be shared across very different cancers."
The team is already evaluating other drugs similar to palbociclib—many also approved for breast cancer—to expand options for future clinical trials. They have not yet tested the combination in patients, but Tyner predicted that it would mitigate most known resistance mechanisms to current standard therapy. Moving the combination into clinical testing will require more work, but the researchers are positioned to pursue it. The question now is whether what works in cells and mice will translate to the clinic, where it might finally shift that stubborn survival curve.
Citações Notáveis
Almost everyone will eventually develop drug resistance to current AML therapy.— Jeffrey Tyner, OHSU professor and study corresponding author
Based on everything we've seen, our prediction is that this combination would mitigate most known resistance mechanisms to current standard therapy.— Jeffrey Tyner
A Conversa do Hearth Outra perspectiva sobre a história
Why does a breast cancer drug work against leukemia? Aren't these completely different diseases?
They are different, but cancer cells share fundamental survival strategies. When you block one pathway, cells find another. Palbociclib blocks protein production—a survival mechanism that AML cells use when they're trying to escape venetoclax. It's not about the cancer type; it's about the vulnerability.
The survival rates are still low even with this combination. Why should patients be hopeful?
Because resistance is the wall everyone hits. Right now, almost everyone develops it. If this combination can delay or prevent that resistance, it changes the timeline and the quality of life. That's not a cure, but it's a real shift.
How confident are the researchers that this will work in actual patients?
They're cautious but optimistic. They've tested it in hundreds of patient samples and in living models. But there's always a gap between the lab and the clinic. That's why the next step is clinical trials. They're not claiming victory yet—they're saying the data is strong enough to try.
What happens if patients develop resistance to this combination too?
That's the honest question. The researchers found that the two drugs work on multiple pathways, not just one, which makes it harder for cells to adapt. But cancer is relentless. The real win here is buying time and keeping more people alive longer while researchers work on what comes next.
Why did it take a breast cancer drug to solve an AML problem?
Because the researchers followed the data, not the tradition. They tested 25 combinations systematically. The best answer came from outside the usual AML playbook. That's how science moves forward—by being willing to look where you haven't looked before.